Proliferation assays utilizing recombinant proteins revealed that among these, NCAM-1 and ICAM-1 robustly increased glioma cell proliferation in two distinct patient-derived glioma models, while SEMA4B, and CLSTN1 had no effect on glioma proliferation (Fig. 3G–I). Here, NCAM1 is linked to central nervous system cancer.